US 10,238,722 B2Granted

Pigment epithelium derived factor (PEDF) for the treatment of uterine fibroids

AssigneeRamot at Tel-Aviv University Ltd.

InventorsRuth Shalgi, Dana Chuderland

Life of this patent

Estimating the term…

Abstract

A method of treating uterine fibroid in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of pigment epithelium-derived factor (PEDF), thereby treating the uterine fibroid in the subject.

Claims19

Dependent claims

A method of treating uterine fibroid in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of pigment epithelium-derived factor (PEDF), thereby treating the uterine fibroid in the subject.

Dependencies are inferred from the claim text.

Facts

Application: 15/525,062Filed 24 Nov 2015 · us provisional application
Priority: 24 Nov 2014
Published: US 2018/0043001 A115 Feb 2018
Granted: 26 Mar 2019
Term ends: Not estimatedThe source records don’t support an estimate.

Classification7 codes

A61K 38/57
Protease inhibitors: from animals; from humans
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 9/0034
Galenical forms characterised by the site of application: urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder;…
A61K 38/18
From animals; from humans: growth factors; Growth regulators

Family

Application62/083,356Us provisional application · filed 24 Nov 2014
US 2018/0043001 A1Pre-grant publication · published 15 Feb 2018
US 10,238,722 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results